31 results about "EYE INFESTATION" patented technology

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.

The present invention provides for the treatment, prevention, and / or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The present invention is one group of carotenoid antioxidant recipe comprising lutin and / or rutin ester, zeaxanthin and / or zeaxanthin ester and other antioxidant. Several medicinal and health care antioxidant products may be produced to avoid, delay or treat the harmful effect of the free radical caused by light, cigarette and hormone to eye, especially its crystalline lens and retina. The present invention is used mainly for the prevention and treatment of age relevant eye diseases, cataract, macular degeneration, etc. Dihydroxy carotenoid and other antioxidant are used to nourish crystalline lens and retina so as to enhance the capacity of eye, especially its crystalline lens and retina, in resisting the effect of outer negative factors.

A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.

The invention relates to composition instant granules for providing nutrients for the macular area of the retina, improving vision and preventing eye diseases and a preparation method thereof, and belongs to the field of functional nutritious food. The composition instant granules are prepared from, by weight, 1.5 parts of a blueberry extract, 5 parts of a bilberry extract, 2.5 parts of a dunaliella salina extract, 0.5 part of zeaxanthin, 0.2 part of lutein ester, 6.5 parts of tea theanine, 10 parts of a fructus lycii extract, 5 parts of a haematococcus pluvialis extract, 5 parts of DHA algaeoil microcapsule powder, 10 parts of acerola cherry fruit powder, 0.15 part of taurine, 0.15 part of zinc gluconate, 0.15 part of calcium, 0.15 part of organic selenium, 0.15 part of vitamin B2, 0.15part of vitamin E, 0.15 part of casein phosphopeptide and 50 parts of xylitol. The composition instant granules can provide the nutrients for the macular area of the retina, delay the increase of thedegree of myopia of adolescents, assist in treating amblyopia of infants, delay the occurrence of presbyopia of middle-aged and elderly people, prevent the eye diseases of middle-aged and elderly people, and assist in treating the eye diseases of middle-aged and elderly people.

The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.

The invention relates to an eye drop, in particular to a penetration promoting and eyesight improving eye drop. The invention aims to solve the problem of treatment period prolongation of an eye disease due to less effective components of the traditional eye drop, which really enter the inner side of an eyeball, by the isolation of a blood-eye barrier, a cornea barrier and an eye surface barrier. A penetration promoting and eyesight improving medicament in the first scheme is any combination of one or more of borneol, menthol, taurochenodeoxycholic acid or tauroursodeoxycholic acid; and a penetration promoting and eyesight improving medicament in the second technical scheme is any combination of one or more of borneol, menthol, chenodeoxycholic acid or ursodesoxycholic acid. The eye drop is used for a patient with conjunctivitis, keratitis and uveitis and used as a penetration promoting agent of other eye drops or an ophthalmic pharmaceutical partner for increasing the amount of the eye drops dropping in eyes. The eye drop can penetrate through the blood-eye barrier, the cornea barrier and the eye surface barrier; and compared with the prior art, the invention can improve the effective component entering the inner side of the eyeballs by 10-200 percent.

The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and / or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders.

Several embodiments disclosed herein relate to the delivery of therapeutic nucleic acids to an ocular tissue in order to provide a therapeutic effect to reduce symptoms of or otherwise alleviate an ocular disorder. In particular embodiments, plasmid DNA is delivered to the cells of the trabecular meshwork in order to ameliorate increasing intraocular pressure. Devices and systems to accomplish this delivery are also disclosed.

The present invention provides a safer and more effective way to treat ophthalmic disease and to perform ophthalmic surgeries while reducing the risk of vision loss due to the inflammatory response in the eye. The invention generally relates to the use of fluoroquinolones to reduce inflammation due to ophthalmic disease or ophthalmic surgery, including treatments for macular degeneration, diabetes, and vascular ischemic diseases, and other ophthalmic diseases. One aspect of the present invention involves using an anti-VEGF medication along with moxifloxacin in treating ophthalmic disease and in reducing inflammatory response in the eye following surgery for treating diseases like wet macular degeneration. Another aspect of the present invention involves delivering a fluoroquinolone combination to the eye in a sustained delivery application or device.

The invention provides methods for treating and / or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.

A quick-acting eye drops without irritation and drug tolerance for treating conjunctivitis, trachoma, keratitis, dacryocystitis, visional fatigue, etc is prepared from coptis root, pale butterflybush flower and monoxydine hydrochloride. Its advantages are high curative effect and quickly taking its effect.

A method comprising the step of: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of pterygium and pinguecula.

Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I:S-(MS)p-(MS)q  General Formula Iwherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue.The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1β, TNF-α, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated eye disease and side effects of wearing of contact lenses. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition. In addition, the composition may be used as a cleaner or a lubricant for contact lenses since it has nonbacterial antiinflammatory activity and ocular contact lubricating activity.